Skip to content

AtaiBeckley

US · ATAI #2575 by market cap Listed 2021
0.00 0.00 0.00%
Periodic snapshot; not a real-time feed. · 2026-11-20 09:30

About AtaiBeckley

AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.

CEO
Mr. Srinivas G. Rao, M.D.,PhD
Employees
117
Fiscal year end
12-31
Website
ataibeckley.com

Company profile

Exchange
US
Symbol
ATAI
Market-cap rank
#2575
Listing date
2021-06-18
Market cap
0
Float cap
0
Shares out
370.86M
Float shares
308.41M

Sectors & themes

Browse all sectors & themes

Quote time 2026-11-20 09:30:00 · For reference only, not investment advice and not tailored to your situation.

AtaiBeckley discussion 0 comments

Add a comment